Cargando…

Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis

BACKGROUND: Heart failure (HF) prognosis without therapy is poor, however introduction of a range of drugs has improved it. We aimed to perform a systematic review on the effects and safety of sodium-glucose transporter 2 inhibitors (SGLT2i) in HF patients. METHODS: We carried out a systematic revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chambergo-Michilot, Diego, Tauma-Arrué, Astrid, Loli-Guevara, Silvana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734238/ https://www.ncbi.nlm.nih.gov/pubmed/33335975 http://dx.doi.org/10.1016/j.ijcha.2020.100690

Ejemplares similares

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis
por: Chambergo-Michilot, Diego, et al.
Publicado: (2023)

Associations between chronic conditions and oral health services utilization in older Peruvian adults: a pooled analysis of the Demographic and Health Survey 2015-2017
por: Azañedo, Diego, et al.
Publicado: (2020)

Efficacy and safety of SGLT2 inhibitors in patients with heart failure: A protocol for systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2022)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
por: Arriola-Montenegro, Jose, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
por: Chambergo-Michilot, Diego, et al.
Publicado: (2022)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Temporal arteritis, Sjögren’s syndrome and mixed pain components as manifestations in a diabetic older adult: systematic review based on a case report
por: Runzer-Colmenares, Fernando M., et al.
Publicado: (2020)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Ul Amin, Noor, et al.
Publicado: (2022)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Efficacy and Safety of Colchicine in Post–acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Diaz-Arocutipa, Carlos, et al.
Publicado: (2021)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
por: Cardoso, Rhanderson, et al.
Publicado: (2021)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials
por: Bazoukis, George, et al.
Publicado: (2021)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
por: Pabel, Steffen, et al.
Publicado: (2021)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
por: Carluccio, Erberto, et al.
Publicado: (2023)

Socioeconomic determinants of hypertension and prehypertension in Peru: Evidence from the Peruvian Demographic and Health Survey
por: Chambergo-Michilot, Diego, et al.
Publicado: (2021)

Acute pulmonary histoplasmosis related to occupational roofing: A case report of two brothers
por: Gnoni, Martin, et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ao7plb7om2cdfprhb5vonr8dk3